Cystinosis: Difference between revisions
Ostermayer (talk | contribs) |
(Strip excess bold) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Cystinosis is a rare autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene, resulting in accumulation of the amino acid cystine within lysosomes of all cells. | |||
*It is the most common inherited cause of [[Fanconi syndrome]] in children.<ref name="StatPearls">Cystinosis. ''StatPearls''. 2024. PMID: 39548762</ref> Emergency physicians encounter cystinosis patients presenting with severe dehydration, electrolyte crises (hypokalemia, metabolic acidosis, hypophosphatemia), renal failure, hypoglycemia, and complications of chronic kidney disease and multiorgan involvement.<ref name="Gahl2002">Gahl WA, Thoene JG, Schneider JA. Cystinosis. ''N Engl J Med''. 2002;347(2):111-121. doi:10.1056/NEJMra020552</ref> | |||
*Incidence approximately 1 in 100,000-200,000 live births<ref name="StatPearls"/> | *Incidence approximately 1 in 100,000-200,000 live births<ref name="StatPearls"/> | ||
*Caused by loss-of-function mutations in | *Caused by loss-of-function mutations in CTNS (chromosome 17p13.2), encoding cystinosin, a lysosomal membrane cystine transporter | ||
*Defective cystinosin → cystine cannot exit lysosomes → | *Defective cystinosin → cystine cannot exit lysosomes → intralysosomal cystine accumulation → intracellular crystal formation → progressive cellular dysfunction and organ damage<ref name="Gahl2002"/> | ||
*Kidneys are the first and most severely affected organ; proximal tubule cells are uniquely vulnerable | *Kidneys are the first and most severely affected organ; proximal tubule cells are uniquely vulnerable | ||
*Without treatment, '''end-stage renal disease (ESRD) by age 10-12 years'''<ref name="StatPearls"/> | *Without treatment, '''end-stage renal disease (ESRD) by age 10-12 years'''<ref name="StatPearls"/> | ||
*With early cysteamine therapy, renal survival is significantly improved and many patients now survive into adulthood, though they develop progressive extrarenal complications | *With early cysteamine therapy, renal survival is significantly improved and many patients now survive into adulthood, though they develop progressive extrarenal complications | ||
* | * Not the same as [[Cystinuria|cystinuria]] (a separate disorder of renal cystine transport causing kidney stones) | ||
===Three clinical forms=== | ===Three clinical forms=== | ||
| Line 26: | Line 26: | ||
====Infant/young child (most common ED presentation)==== | ====Infant/young child (most common ED presentation)==== | ||
*Presentation typically at | *Presentation typically at 6-18 months with features of [[Fanconi syndrome]]: | ||
**Polyuria, polydipsia (often severe) | **Polyuria, polydipsia (often severe) | ||
** | ** Severe dehydration and volume depletion (the primary reason for ED visits in young children)<ref name="Nesterova2008">Nesterova G, Gahl W. Nephropathic cystinosis: late complications of a multisystemic disease. ''Pediatr Nephrol''. 2008;23(6):863-878. doi:10.1007/s00467-007-0535-x</ref> | ||
**Recurrent vomiting | **Recurrent vomiting | ||
** | ** Failure to thrive, growth retardation | ||
**Unexplained fevers (from dehydration) | **Unexplained fevers (from dehydration) | ||
**Constipation alternating with diarrhea | **Constipation alternating with diarrhea | ||
* | * Rickets: bowed legs, widened wrists, bone pain, pathologic fractures (from phosphate wasting + impaired vitamin D activation) | ||
* | * Blonde hair and fair complexion — characteristically lighter pigmentation than siblings (impaired melanin synthesis from cystine accumulation)<ref name="Orphanet2016">Elmonem MA, et al. Cystinosis: a review. ''Orphanet J Rare Dis''. 2016;11:47. doi:10.1186/s13023-016-0426-y</ref> | ||
====Older child/adolescent/adult==== | ====Older child/adolescent/adult==== | ||
* | * Chronic kidney disease — may present with complications of CKD/ESRD (fluid overload, [[Hyperkalemia|hyperkalemia]], uremia, [[Pulmonary edema|pulmonary edema]]) | ||
* | * Post-transplant complications — kidney transplant does NOT cure cystinosis; cystine continues to accumulate systemically | ||
*Progressive | *Progressive extrarenal complications (see below) | ||
====Electrolyte emergencies (any age)==== | ====Electrolyte emergencies (any age)==== | ||
* | * [[Hypokalemia]] — may be severe and life-threatening (from Fanconi syndrome renal wasting) | ||
* | * [[Metabolic acidosis]] — non-anion gap, hyperchloremic (proximal type 2 [[Renal tubular acidosis|RTA]]) | ||
* | * [[Hypophosphatemia]] | ||
* | * Hyponatremia (from renal sodium wasting and free water excess) | ||
* | * [[Hypoglycemia]] (especially in infants during intercurrent illness) | ||
===Extrarenal manifestations (progressive with age)=== | ===Extrarenal manifestations (progressive with age)=== | ||
* | * Ocular: corneal cystine crystals visible on slit-lamp examination — pathognomonic finding that can clinch the diagnosis; photophobia, tearing, blepharospasm, retinal depigmentation<ref name="Gahl2002"/> | ||
* | * Endocrine: hypothyroidism (most common; >70% of patients), insulin-dependent diabetes mellitus (pancreatic involvement), hypogonadism, delayed puberty | ||
* | * Muscular: progressive distal myopathy, dysphagia and swallowing dysfunction (risk of aspiration pneumonia — a potentially lethal complication)<ref name="Orphanet2016"/> | ||
* | * Neurologic: encephalopathy, cognitive impairment, seizures, intracranial calcifications, cerebral atrophy | ||
* | * Hepatic: hepatomegaly, portal hypertension (nodular regenerative hyperplasia) | ||
* | * Pulmonary: restrictive lung disease from myopathy | ||
==Differential diagnosis== | ==Differential diagnosis== | ||
| Line 72: | Line 72: | ||
*Reflux nephropathy | *Reflux nephropathy | ||
*[[Focal segmental glomerulosclerosis]] | *[[Focal segmental glomerulosclerosis]] | ||
{{Renal tubular disorders DDX}} | |||
==Evaluation== | ==Evaluation== | ||
===EM workup=== | ===EM workup=== | ||
* | * BMP: hypokalemia, hypophosphatemia, low bicarbonate (non-anion gap metabolic acidosis), elevated creatinine/BUN, hyponatremia | ||
* | * Blood glucose: hypoglycemia (especially infants) | ||
* | * ABG/VBG: non-anion gap metabolic acidosis (proximal RTA) | ||
* | * Urinalysis: | ||
** | ** Glycosuria with normal serum glucose (hallmark of Fanconi syndrome) | ||
**Generalized aminoaciduria, proteinuria (low-molecular-weight) | **Generalized aminoaciduria, proteinuria (low-molecular-weight) | ||
**Phosphaturia | **Phosphaturia | ||
* | * CBC: may show anemia of CKD | ||
* | * Calcium, magnesium, phosphate, uric acid, vitamin D, PTH | ||
* | * TSH, free T4: hypothyroidism is common and may be undiagnosed | ||
* | * ECG: if hypokalemia or hyperkalemia suspected | ||
===Diagnostic clue for the undiagnosed child=== | ===Diagnostic clue for the undiagnosed child=== | ||
* | * Slit-lamp examination: corneal cystine crystals (refractile, needle-shaped crystals in the corneal stroma) — visible by approximately 1 year of age; pathognomonic for cystinosis<ref name="Gahl2002"/> | ||
*If cystinosis is suspected, order '''white blood cell (WBC) cystine level''' — the gold standard diagnostic and monitoring test (normal <0.2 nmol half-cystine/mg protein; cystinosis patients typically 3-23 nmol)<ref name="StatPearls"/> | *If cystinosis is suspected, order '''white blood cell (WBC) cystine level''' — the gold standard diagnostic and monitoring test (normal <0.2 nmol half-cystine/mg protein; cystinosis patients typically 3-23 nmol)<ref name="StatPearls"/> | ||
*Confirmed by | *Confirmed by CTNS gene mutation analysis | ||
*These confirmatory tests are NOT available in the ED but should be arranged via nephrology/genetics referral | *These confirmatory tests are NOT available in the ED but should be arranged via nephrology/genetics referral | ||
===When to suspect cystinosis in the ED=== | ===When to suspect cystinosis in the ED=== | ||
*Infant (6-18 months) with | *Infant (6-18 months) with unexplained failure to thrive + polyuria + severe dehydration + metabolic acidosis | ||
*Child with | *Child with Fanconi syndrome (glycosuria + aminoaciduria + phosphaturia + bicarbonaturia) — cystinosis is the most common inherited cause | ||
* | * Blonde child who is lighter than siblings with renal disease | ||
*Any patient with | *Any patient with corneal crystals on eye examination | ||
==Management== | ==Management== | ||
===Acute ED management=== | ===Acute ED management=== | ||
* | * Dehydration: aggressive IV fluid resuscitation — cystinosis children can have massive free water losses from polyuria and may need large volumes<ref name="Nesterova2008"/> | ||
**Use isotonic saline initially; switch to maintenance fluids with appropriate electrolyte composition once volume repleted | **Use isotonic saline initially; switch to maintenance fluids with appropriate electrolyte composition once volume repleted | ||
** | ** Caution: these patients may lose 2-3 L/m²/day of free water; calculate maintenance + ongoing losses carefully | ||
* | * Hypokalemia: | ||
**IV and PO potassium repletion | **IV and PO potassium repletion | ||
**May be refractory due to ongoing renal losses | **May be refractory due to ongoing renal losses | ||
**Continuous cardiac monitoring if K⁺ <3.0 mEq/L | **Continuous cardiac monitoring if K⁺ <3.0 mEq/L | ||
* | * Metabolic acidosis: | ||
**IV sodium bicarbonate for severe acidosis (pH <7.2) | **IV sodium bicarbonate for severe acidosis (pH <7.2) | ||
**Replete potassium FIRST or concurrently (bicarbonate worsens hypokalemia) | **Replete potassium FIRST or concurrently (bicarbonate worsens hypokalemia) | ||
* | * Hypophosphatemia: | ||
**IV phosphate if severe (<1 mg/dL) or symptomatic | **IV phosphate if severe (<1 mg/dL) or symptomatic | ||
**Oral phosphate supplementation for less acute presentations | **Oral phosphate supplementation for less acute presentations | ||
* | * Hypoglycemia: IV dextrose | ||
* | * Hypothyroidism: ensure patient is on levothyroxine if known cystinosis patient; do not discontinue | ||
* | * Hyperkalemia/uremia/fluid overload (in ESRD patients): manage per standard CKD emergency protocols; dialysis if indicated | ||
===Disease-specific therapy=== | ===Disease-specific therapy=== | ||
* | * Cysteamine (cysteamine bitartrate; Cystagon, Procysbi) — the '''only disease-modifying therapy'''<ref name="StatPearls"/> | ||
**Depletes intralysosomal cystine by forming a mixed disulfide that can exit lysosomes via an alternative transporter | **Depletes intralysosomal cystine by forming a mixed disulfide that can exit lysosomes via an alternative transporter | ||
**'''Do NOT discontinue cysteamine''' in the ED unless there is a specific contraindication — missed doses lead to cystine reaccumulation | **'''Do NOT discontinue cysteamine''' in the ED unless there is a specific contraindication — missed doses lead to cystine reaccumulation | ||
**If the patient cannot take oral medications (vomiting, intubation), contact their nephrologist/metabolic specialist for guidance on holding cysteamine | **If the patient cannot take oral medications (vomiting, intubation), contact their nephrologist/metabolic specialist for guidance on holding cysteamine | ||
**Common side effects: GI upset (nausea, vomiting, diarrhea), breath/body odor (sulfurous), skin rash | **Common side effects: GI upset (nausea, vomiting, diarrhea), breath/body odor (sulfurous), skin rash | ||
**Cysteamine does | **Cysteamine does not reverse established Fanconi syndrome; it slows progression to ESRD and delays extrarenal complications | ||
* | * Cysteamine eye drops (Cystadrops): topical treatment for corneal cystine crystals; patients may present with ocular complaints if drops are missed | ||
* | * Indomethacin (1-3 mg/kg/day): used in some patients to reduce polyuria/prostaglandin-mediated renal losses | ||
** | ** Discontinue during acute dehydration or illness — can worsen renal function | ||
**'''Do NOT combine with ACE inhibitors''' — risk of acute GFR decline<ref name="StatPearls"/> | **'''Do NOT combine with ACE inhibitors''' — risk of acute GFR decline<ref name="StatPearls"/> | ||
===Intercurrent illness ("sick day" management)=== | ===Intercurrent illness ("sick day" management)=== | ||
*Cystinosis patients are at | *Cystinosis patients are at high risk for rapid, severe dehydration during any intercurrent illness (gastroenteritis, febrile illness) due to their massive baseline renal water losses<ref name="Nesterova2008"/> | ||
*Low threshold for admission and IV fluids | *Low threshold for admission and IV fluids | ||
*Monitor electrolytes frequently (q4-6 hours) during acute illness | *Monitor electrolytes frequently (q4-6 hours) during acute illness | ||
| Line 138: | Line 141: | ||
==Disposition== | ==Disposition== | ||
* | * Severe dehydration, significant electrolyte abnormalities, or hemodynamic instability: admit for IV resuscitation, continuous monitoring, serial electrolytes | ||
* | * Infant with new-onset failure to thrive + Fanconi syndrome features: admit for evaluation and stabilization; nephrology and genetics consultation | ||
* | * Known cystinosis patient with mild dehydration responding to IV fluids, stable electrolytes: may consider discharge with close follow-up if reliable caregiver, PO tolerance established, and outpatient team notified | ||
* | * Any intercurrent illness in an infant/young child with cystinosis: low threshold for admission — these patients decompensate quickly<ref name="Nesterova2008"/> | ||
* | * ESRD complications (hyperkalemia, pulmonary edema, uremia): admit; nephrology/dialysis consultation | ||
* | * Aspiration pneumonia (from progressive myopathy/dysphagia): admit; may need ICU if respiratory failure | ||
*Ensure | *Ensure cysteamine is continued (or restarted ASAP) | ||
*Communicate with the patient's | *Communicate with the patient's nephrology/metabolic team — these patients are followed closely and their specialists should be notified of all ED visits | ||
==See Also== | ==See Also== | ||
Latest revision as of 09:32, 22 March 2026
Background
- Cystinosis is a rare autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene, resulting in accumulation of the amino acid cystine within lysosomes of all cells.
- It is the most common inherited cause of Fanconi syndrome in children.[1] Emergency physicians encounter cystinosis patients presenting with severe dehydration, electrolyte crises (hypokalemia, metabolic acidosis, hypophosphatemia), renal failure, hypoglycemia, and complications of chronic kidney disease and multiorgan involvement.[2]
- Incidence approximately 1 in 100,000-200,000 live births[1]
- Caused by loss-of-function mutations in CTNS (chromosome 17p13.2), encoding cystinosin, a lysosomal membrane cystine transporter
- Defective cystinosin → cystine cannot exit lysosomes → intralysosomal cystine accumulation → intracellular crystal formation → progressive cellular dysfunction and organ damage[2]
- Kidneys are the first and most severely affected organ; proximal tubule cells are uniquely vulnerable
- Without treatment, end-stage renal disease (ESRD) by age 10-12 years[1]
- With early cysteamine therapy, renal survival is significantly improved and many patients now survive into adulthood, though they develop progressive extrarenal complications
- Not the same as cystinuria (a separate disorder of renal cystine transport causing kidney stones)
Three clinical forms
| Form | Frequency | Onset | Key features |
|---|---|---|---|
| Infantile (nephropathic) | ~95% | 6-12 months | Fanconi syndrome → ESRD by 10-12 yr; systemic disease |
| Juvenile (intermediate) | ~5% | Late childhood/adolescence | Slower progression; may present with proteinuria alone |
| Adult (ocular/non-nephropathic) | Rare | Adulthood | Corneal crystals and photophobia only; no renal disease |
Clinical features
What the EM physician will see
Infant/young child (most common ED presentation)
- Presentation typically at 6-18 months with features of Fanconi syndrome:
- Polyuria, polydipsia (often severe)
- Severe dehydration and volume depletion (the primary reason for ED visits in young children)[3]
- Recurrent vomiting
- Failure to thrive, growth retardation
- Unexplained fevers (from dehydration)
- Constipation alternating with diarrhea
- Rickets: bowed legs, widened wrists, bone pain, pathologic fractures (from phosphate wasting + impaired vitamin D activation)
- Blonde hair and fair complexion — characteristically lighter pigmentation than siblings (impaired melanin synthesis from cystine accumulation)[4]
Older child/adolescent/adult
- Chronic kidney disease — may present with complications of CKD/ESRD (fluid overload, hyperkalemia, uremia, pulmonary edema)
- Post-transplant complications — kidney transplant does NOT cure cystinosis; cystine continues to accumulate systemically
- Progressive extrarenal complications (see below)
Electrolyte emergencies (any age)
- Hypokalemia — may be severe and life-threatening (from Fanconi syndrome renal wasting)
- Metabolic acidosis — non-anion gap, hyperchloremic (proximal type 2 RTA)
- Hypophosphatemia
- Hyponatremia (from renal sodium wasting and free water excess)
- Hypoglycemia (especially in infants during intercurrent illness)
Extrarenal manifestations (progressive with age)
- Ocular: corneal cystine crystals visible on slit-lamp examination — pathognomonic finding that can clinch the diagnosis; photophobia, tearing, blepharospasm, retinal depigmentation[2]
- Endocrine: hypothyroidism (most common; >70% of patients), insulin-dependent diabetes mellitus (pancreatic involvement), hypogonadism, delayed puberty
- Muscular: progressive distal myopathy, dysphagia and swallowing dysfunction (risk of aspiration pneumonia — a potentially lethal complication)[4]
- Neurologic: encephalopathy, cognitive impairment, seizures, intracranial calcifications, cerebral atrophy
- Hepatic: hepatomegaly, portal hypertension (nodular regenerative hyperplasia)
- Pulmonary: restrictive lung disease from myopathy
Differential diagnosis
Infant with failure to thrive, polyuria, and dehydration
- Diabetes mellitus (type 1)
- Diabetes insipidus
- Bartter syndrome
- Other causes of Fanconi syndrome (see Fanconi syndrome#Differential diagnosis)
- Galactosemia
- Tyrosinemia
- Urinary tract infection/pyelonephritis
- Child abuse/neglect
Older child/adult with CKD
- Other causes of Chronic kidney disease
- IgA nephropathy
- Reflux nephropathy
- Focal segmental glomerulosclerosis
Renal tubular disorders
- Salt-wasting tubulopathies
- Gitelman syndrome — distal convoluted tubule (NCC defect); hypokalemia, hypomagnesemia, hypocalciuria, metabolic alkalosis
- Bartter syndrome — thick ascending limb (NKCC2/ROMK/ClC-Kb defect); hypokalemia, hypercalciuria, metabolic alkalosis
- Liddle syndrome — collecting duct (ENaC gain-of-function); hypokalemia, hypertension, metabolic alkalosis
- Renal tubular acidosis
- Renal tubular acidosis type I (distal) — hypokalemia, metabolic acidosis, nephrocalcinosis
- Renal tubular acidosis type II (proximal) — hypokalemia, metabolic acidosis, Fanconi syndrome
- Renal tubular acidosis type IV — hyperkalemia, metabolic acidosis, hypoaldosteronism
- Inherited disorders of tubular transport
- Cystinuria — proximal tubule amino acid transport defect; recurrent cystine stones
- Fanconi syndrome — proximal tubule generalized dysfunction; glucosuria, aminoaciduria, phosphaturia
- Nephrogenic diabetes insipidus — collecting duct (aquaporin/V2R defect); polyuria, hypernatremia
- Dent disease — proximal tubule (ClC-5 defect); low molecular weight proteinuria, nephrocalcinosis
- Acquired tubulopathies
- Diuretic use/abuse (thiazide mimics Gitelman; loop mimics Bartter)
- Aminoglycosides nephrotoxicity
- Cisplatin nephrotoxicity
- Amphotericin B nephrotoxicity
- Lithium-induced nephrogenic DI
Evaluation
EM workup
- BMP: hypokalemia, hypophosphatemia, low bicarbonate (non-anion gap metabolic acidosis), elevated creatinine/BUN, hyponatremia
- Blood glucose: hypoglycemia (especially infants)
- ABG/VBG: non-anion gap metabolic acidosis (proximal RTA)
- Urinalysis:
- Glycosuria with normal serum glucose (hallmark of Fanconi syndrome)
- Generalized aminoaciduria, proteinuria (low-molecular-weight)
- Phosphaturia
- CBC: may show anemia of CKD
- Calcium, magnesium, phosphate, uric acid, vitamin D, PTH
- TSH, free T4: hypothyroidism is common and may be undiagnosed
- ECG: if hypokalemia or hyperkalemia suspected
Diagnostic clue for the undiagnosed child
- Slit-lamp examination: corneal cystine crystals (refractile, needle-shaped crystals in the corneal stroma) — visible by approximately 1 year of age; pathognomonic for cystinosis[2]
- If cystinosis is suspected, order white blood cell (WBC) cystine level — the gold standard diagnostic and monitoring test (normal <0.2 nmol half-cystine/mg protein; cystinosis patients typically 3-23 nmol)[1]
- Confirmed by CTNS gene mutation analysis
- These confirmatory tests are NOT available in the ED but should be arranged via nephrology/genetics referral
When to suspect cystinosis in the ED
- Infant (6-18 months) with unexplained failure to thrive + polyuria + severe dehydration + metabolic acidosis
- Child with Fanconi syndrome (glycosuria + aminoaciduria + phosphaturia + bicarbonaturia) — cystinosis is the most common inherited cause
- Blonde child who is lighter than siblings with renal disease
- Any patient with corneal crystals on eye examination
Management
Acute ED management
- Dehydration: aggressive IV fluid resuscitation — cystinosis children can have massive free water losses from polyuria and may need large volumes[3]
- Use isotonic saline initially; switch to maintenance fluids with appropriate electrolyte composition once volume repleted
- Caution: these patients may lose 2-3 L/m²/day of free water; calculate maintenance + ongoing losses carefully
- Hypokalemia:
- IV and PO potassium repletion
- May be refractory due to ongoing renal losses
- Continuous cardiac monitoring if K⁺ <3.0 mEq/L
- Metabolic acidosis:
- IV sodium bicarbonate for severe acidosis (pH <7.2)
- Replete potassium FIRST or concurrently (bicarbonate worsens hypokalemia)
- Hypophosphatemia:
- IV phosphate if severe (<1 mg/dL) or symptomatic
- Oral phosphate supplementation for less acute presentations
- Hypoglycemia: IV dextrose
- Hypothyroidism: ensure patient is on levothyroxine if known cystinosis patient; do not discontinue
- Hyperkalemia/uremia/fluid overload (in ESRD patients): manage per standard CKD emergency protocols; dialysis if indicated
Disease-specific therapy
- Cysteamine (cysteamine bitartrate; Cystagon, Procysbi) — the only disease-modifying therapy[1]
- Depletes intralysosomal cystine by forming a mixed disulfide that can exit lysosomes via an alternative transporter
- Do NOT discontinue cysteamine in the ED unless there is a specific contraindication — missed doses lead to cystine reaccumulation
- If the patient cannot take oral medications (vomiting, intubation), contact their nephrologist/metabolic specialist for guidance on holding cysteamine
- Common side effects: GI upset (nausea, vomiting, diarrhea), breath/body odor (sulfurous), skin rash
- Cysteamine does not reverse established Fanconi syndrome; it slows progression to ESRD and delays extrarenal complications
- Cysteamine eye drops (Cystadrops): topical treatment for corneal cystine crystals; patients may present with ocular complaints if drops are missed
- Indomethacin (1-3 mg/kg/day): used in some patients to reduce polyuria/prostaglandin-mediated renal losses
- Discontinue during acute dehydration or illness — can worsen renal function
- Do NOT combine with ACE inhibitors — risk of acute GFR decline[1]
Intercurrent illness ("sick day" management)
- Cystinosis patients are at high risk for rapid, severe dehydration during any intercurrent illness (gastroenteritis, febrile illness) due to their massive baseline renal water losses[3]
- Low threshold for admission and IV fluids
- Monitor electrolytes frequently (q4-6 hours) during acute illness
- Hold indomethacin during dehydration
- Continue cysteamine if tolerated; if not, resume as soon as possible
Disposition
- Severe dehydration, significant electrolyte abnormalities, or hemodynamic instability: admit for IV resuscitation, continuous monitoring, serial electrolytes
- Infant with new-onset failure to thrive + Fanconi syndrome features: admit for evaluation and stabilization; nephrology and genetics consultation
- Known cystinosis patient with mild dehydration responding to IV fluids, stable electrolytes: may consider discharge with close follow-up if reliable caregiver, PO tolerance established, and outpatient team notified
- Any intercurrent illness in an infant/young child with cystinosis: low threshold for admission — these patients decompensate quickly[3]
- ESRD complications (hyperkalemia, pulmonary edema, uremia): admit; nephrology/dialysis consultation
- Aspiration pneumonia (from progressive myopathy/dysphagia): admit; may need ICU if respiratory failure
- Ensure cysteamine is continued (or restarted ASAP)
- Communicate with the patient's nephrology/metabolic team — these patients are followed closely and their specialists should be notified of all ED visits
See Also
- Fanconi syndrome
- Fanconi anemia (a completely different condition)
- Renal tubular acidosis
- Hypokalemia
- Metabolic acidosis
- Chronic kidney disease
- Failure to thrive
- Cystinuria
External Links
- StatPearls — Cystinosis
- Orphanet J Rare Dis — Cystinosis: a review (2016)
- Nat Rev Nephrol — The renal Fanconi syndrome in cystinosis (2017)
- Cystinosis Research Network
- Fanconi Anemia Research Fund (for distinguishing from Fanconi anemia)
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Cystinosis. StatPearls. 2024. PMID: 39548762
- ↑ 2.0 2.1 2.2 2.3 Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med. 2002;347(2):111-121. doi:10.1056/NEJMra020552
- ↑ 3.0 3.1 3.2 3.3 Nesterova G, Gahl W. Nephropathic cystinosis: late complications of a multisystemic disease. Pediatr Nephrol. 2008;23(6):863-878. doi:10.1007/s00467-007-0535-x
- ↑ 4.0 4.1 Elmonem MA, et al. Cystinosis: a review. Orphanet J Rare Dis. 2016;11:47. doi:10.1186/s13023-016-0426-y
